Influenza Vaccines and Vaccination Strategies

The Vaccine Book: Second Edition

Volumn , Issue , 2016, Pages 423-444

  Neuzil, Kathleen Maletic ^a,c   Ortiz, Justin R ^b  

^a University of Maryland School of Medicine Center for Vaccine Development   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Hemagglutinin (HA); Influenza virus; Live attenuated influenza vaccines (LAIVs); Non replicating vaccines; Vaccine safety

Indexed keywords

EID: 84987904743     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-802174-3.00021-7     Document Type: Chapter

References (78)

1. Russell R.J., Gamblin S.J., Skehel J.J. Influenza glycoproteins: hemagglutinin and neuraminidase. Textbook of Influenza 2013, Wiley Blackwell, West Sussex, UK. 2nd ed. R.G. Wester, A.S. Monto, T.J. Braciale, R.S. Lamb (Eds.).
2. Prevention and control of influenza with vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb Mortal Wkly Rep 2010, 59(RR-8):1-62. CDC.
3. WHO influenza. http://www.who.int/influenza/human_animal_interface/virology_laboratories_and_vaccines/influenza_virus_infections_humans_feb14.pdf?ua=1.
4. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., Bridges C.B., Grijalva C.G., Zhu Y., Bernstein D.I., Herrera G., Erdman D., Hall C.B., Seither R., Griffin M.R. The underrecognized burden of influenza in young children. N Engl J Med 2006 Jul 6, 355(1):31-40. New Vaccine Surveillance Network.
5. Neuzil K.M., Reed G.W., Mitchel E.F., Griffin M.R. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999, 281:901-907.
6. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. Impact of influenza on hospitalizations, outpatient visits and antibiotic prescriptions in children. New Engl J Med 2000, 342:225-231.
7. Murry J., Cohen A., Walaza S., Groome M., Madhi S., Variava E., et al. Determining the provincial and national burden of influenza-associated severe acute respiratory illness in South Africa using a rapid assessment methodology. PLoS One 2015, 10(7):e0132078.
8. Katz M.A., Tharmaphornpilas P., Chantra S., et al. Who gets hospitalized for influenza pneumonia in Thailand?. Vaccine 2007, 25(19):3827-3833.
9. Brooks W.A., Terebuh P., Bridges C., et al. Influenza A and B infection in children in urban slum, Bangladesh. Emerg Infect Dis 2007, 13(10):1507-1508.
10. Ortiz J.R., Sotomayor V., Uez O.C., Oliva O., Bettels D., McCarron M., Bresee J.S., Mounts A.W. Strategy to enhance influenza surveillance worldwide. Emerg Infect Dis 2009, 15(8):1271-1278.
11. Rudan I., Boschi-Pinto C., Biloglav Z., Mulholland K., Campbell H. Epidemiology and etiology of childhood pneumonia. Bull World Health Organ 2008, 86(5):408-416.
12. Cohen C., Simonsen L., Kang J.W., Miller M., McAnerney J., Blumberg L., et al. Elevated influenza-related excess mortality in South African elderly individuals, 1998-2005. Clin Infect Dis 2010, 51(12):1362-1369.
13. Cohen C., Moyes J., Tempis S., Groome M., Walaza S., Pretorius M., et al. Mortality amongst patients with influenza-associated severe acute respiratory illness, South Africa, 2009-2013. PLoS One 2015, 10(3):e0118884.
14. CDC. Updated CDC estimates of 2009 H1N1 influenza cases, hospitalizations and deaths in the United States, April 2009-February 13, 2010. //222.cdc.gov/h1n1flu/estimates_2009_h1N1.htm.
15. Johnson N.P., Mueller J. Updating the accounts: Global mortality of the 1918-1920 "Spanish" influenza pandemic. Bull Hist Med 2002, 76(1):105-115.
16. Murray C.J., Lopez A.D., Chin B., et al. Estimation of potential global pandemic influenza mortality on the basis of vital registry data from the 1918-20 pandemic: a quantitative analysis. Lancet 2006, 368(9554):2211-2218.
17. Harper S., Klimov A., Uyeki T., et al. Influenza. Clin Laborat Med 2002, 22(4):863-882.
18. WHO Vaccines against influenza WHO position paper. Wkly Epidemiol Rec 2012, 87(47):461-476.
19. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., Wright P.F. The burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185:147-152.
20. Victor JC. Effectiveness of seasonal influenza vaccination of children in tropical developing Africa: a cluster-randomized trial. Options for the Control of Influenza VIII, Cape Town, South Africa; 2013.
21. Brooks W.A., Goswami D., Rahman M., Nahar K., Fry A.M., Balish A., et al. Influenza is a major contributor to childhood pneumonia in a tropical developing country. Pediatr Infect Dis J 2010, 29:216-221.
22. CDC Influenza outbreak-Madagascar. July-August 2002. Morb Mortal Wkly Rep 2002, 51(45):1016-1018.
23. Outbreak of influenza, Madagascar, July-August 2002. Wkly Epidemiol Rec 2002, 77(46):381-384. WHO.
24. Nair H., Brooks W.A., Katz M., Roca A., Berkley J.A., Madhi S.A., et al. Global burden of respiratory infections due to seasonal influenza in young children: a systematic review and meta-analysis. Lancet 2001, 1917-1930.
25. CDC Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on immunization practices, United States, 2015-16 influenza season. MMWR Weekly Report August 7, 2015, 64(30):818-825.
26. Influenza vaccines in Canada. http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/15vol41/dr-rm41-10/ar-02-eng.php.
27. Keitel W.A., Neuzil K.M., Treanor J. Immunogenicity and efficacy of inactivated/live virus seasonal and pandemic vaccines. Textbook of influenza 2013, Wiley Blackwell, West Sussex, UK. 2nd ed. R.G. Wester, A.S. Monto, T.J. Braciale, R.S. Lamb (Eds.).
28. Vesikari T., Knuf M., Wutzler P., Karvonen A., Kieninger-Baum D., Schmitt H.-J., et al. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N Engl J Med 2011, 365:1406-1416.
29. France E.K., Glanz J.M., Xu S., Davis R.L., Black S.B., Shinefield H.R., et al. Safety of the trivalent inactivated influenza vaccine among children-a population-based study. Archiv Pediatr Adoles Med 2004, 158(11):1031-1036. 2004/11.
30. Global Advisory Committee on Vaccine Safety, 11-2 December 2013. Wkly Epidemiol Rec 2014 Feb 14;89(7):53-60.
31. CDC Prevention and control of influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2012-13 influenza season. Morb Mortal Wkly Rep 2012, 61(32):613-618.
32. Falsey A.R., Treanor J.J., Tornieporth N., Capellan J., Gorse G.J. Superior immunogenicity of high dose influenza vaccine compared with standard influenza vaccine in adults > 65 years of age: a randomized double-blined controlled phase 3 trial. J Infect Dis 2008, 200:172-180.
33. DiazGranados C.A., Dunning A.J., Kimmel M., Kirby D., Treanor J., Collins A., Pollak R., Christoff J., Earl J., Landolfi V., Martin E., Gurunathan S., Nathan R., Greenberg D.P., Tornieporth N.G., Decker M.D., Talbot H.K. Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med 2014, 371(7):635-645.
34. Keller-Stanislawski B., Englund J.A., Kang G., Mangtani P., Neuzil K.M., Nohynek H., Pless R., Lambach P., Zuber P. Safety of immunization during pregnancy: a review of the evidence of selected inactivated and live attenuated vaccines. Vaccine 2014, 32(52):7057-7064.
35. Ortiz J.R., Englund J.A., Neuzil K.M. Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 2011, 29(27):4439-4452.
36. Tamma P.D., Sult K.S., delRio D., Steinhoff M.C., Halsey N.A., Omer S.B. Safety of influenza vaccination during pregnancy. Am J Obstetr Gynecol 2009, 547-553.
37. Madhi S.A., Cutland C.L., Locadiah K., Weinberg A., Hugo A., Jones S., Adrian P.V., van Niekerk N., Treurnicht F., Ortiz J.R., Venter M., Violari A., Neuzil K.M., Simoes E.A., Klugman K.P., Nunes M. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 2014, 371(24):2340.
38. Skowronski D.M., Jacobsen K., Daigneault J., Remple V.P., Gagnon L., Daly P., Arsenault G., Landry M., Pielak K., Duval B., Tam T., De Serres G. Solicited adverse events after influenza immunization among infants, toddlers, and their household contacts. Pediatrics 2006, 117(6):1963-1971.
39. Izikson R., Leffell D.J., Bock S.A., Patriarca P.A., Post P., Dunkle L.M., Cox M.J. Randomized comparison of the safety of Flublok® versus licensed inactivated influenza vaccine in healthy, medically stable adults ?50 years of age. Vaccine 2015, 33(48):6622-6628.
40. Lasky T., Tarracciano G.J., Magder L., Koski C.L., Ballesteros M., Nash D., et al. The Guillan-Barre syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998, 339(25):1797-1802.
41. Global Advisory Committee on Vaccine Safety, 12-13 June 2013. Wkly Epidemiol Rec 2013;88(29):301-312.
42. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., Himanen S.L., Hublin C., Julkunen I., Olsén P., Saarenpää-Heikkilä O., Kilpi T. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS One 2012, 7(3):e33536.
43. Crucitti A., Tsai T.F. Explorations of clinical trials and pharmacovigilance databases of MF59®-adjuvanted influenza vaccines for associated cases of narcolepsy: a six-month update. Scand J Infect Dis 2011, 43(11-12):993.
44. Wright P.F., Dolin R., La Montagne J.R. From the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, the Center for Disease Control, and the Bureau of Biologics of the Food and Drug Administration. Summary of clinical trials of influenza vaccines-II. J Infect Dis 1976, 134(6):633-638.
45. Englund J.A., Walter E., Fairchok M., Monto A., Neuzil K.M. A comparison of two influenza vaccine schedules in 6-23-month-old children. Pediatrics 2005, 115:1039-1047.
46. Osterholm M.T., Kelley N.S., Sommer A., Belongia E. Influenza vaccine efficacy and effectiveness: a new look at the evidence. Lancet Infect Dis 2012, 12:36-44.
47. Early estimates of seasonal influenza vaccine effectiveness-United States, January 2015. Morb Mortal Wkly Rep 2015, 64:10-15. CDC.
48. Skowronski D.M., Janjua N.Z., de Serres G., Winter A.-L., Dickinson J.A., Gardy J.L., et al. A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis 2012, 55:332-342.
49. Hoberman A., Greenberg D.P., Paradise J.L., Rockette H.E., Lave J.R., Kearney D.H., Colborn D.K., Kurs-Lasky M., Haralam M.A., Byers C.J., Zoffel L.M., Fabian I.A., Bernard B.S., Kerr J.D. Effectiveness of inactivated influenza vaccine in preventing acute otitis media in young children: a randomized controlled trial. JAMA 2003, 290(12):1608-1616.
50. Ferdinands J.M., Olsho L.E., Agan A.A., Bhat N., Sullivan R.M., Hall M., Mourani P.M., Thompson M., Randolph A.G. Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network. Effectiveness of influenza vaccine against life-threatening RT-PCR-confirmed influenza illness in US children, 2010-2012. J Infect Dis 2014, 210(5):674-683.
51. Zaman K., Roy E., Arifeen S.E., Rahman M., Raquib R., Wilson E., et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 2008, 359:1555-1564.
52. Govaert T.M., Thijs C.T., Masurel N., Sprenger M.J., Dinant G.J., Knottnerus J.A. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. J Am Med Asso 1994, 272(16):1956-1961.
53. Frey S.E., Reyes M.R., Reynales H., Bermal N.N., Nicolay U., Narasimhan V., Forleo-Neto E., Arora A.K. Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine 2014, 32(39):5027-5034.
54. Van Buynder PG, Konrad S., Van Buynder J.L., Brodkin E., Krajden M., Ramler G., Bigham M. The comparative effectiveness of adjuvanted and unadjuvanted trivalent inactivated influenza vaccine (TIV) in the elderly. Vaccine 2013, 31(51):6122-6128.
55. Kendal A.P., Maassab H.F., Alexandrova G.I., Ghendon Y.Z. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the U.S.A. and U.S.S.R. Antivir Res 1982, 1(6):339-365.
56. Dhere R., Yeolekar L., Kulkarni P., et al. A pandemic influenza vaccine in India: from strain to sale within 12 months. Vaccine 2011, 29(Suppl. 1):A16-A21.
57. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011, 5(2):67-75.
58. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181:1133-1137.
59. Hoft D.F., Babusis E., Worku S., Spencer C.T., Lottenbach K., Truscott S.M., et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T cell responses in young children. J Infect Dis 2011, 204:845-853.
60. Plotkin S.A. Correlates of protection induced by vaccination. Clin Vaccine Immunol 2010, 17(7):1055-1065.
61. Forrest B.D., Pride M.W., Dunning A.J., Rosario M., Capeding Z., Chotpitayasunondh T., et al. Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 2008, 15:1042-1053.
62. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356(7):685-696.
63. MedImmune. FluMist (package insert). Federal Drug Administration; 2011.
64. Ortiz J.R., Goswami D., Lewis K.D., Sharmeen A.T., Ahmed M., Rahman M., Rahman M.Z., Feser J., Neuzil K.M., Brooks W.A. Safety of Russian-backbone seasonal trivalent, live-attenuated influenza vaccine in a phase II randomized placebo-controlled clinical trial among children in urban Bangladesh. Vaccine 2015, 33(29):3415-3421.
65. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated cold-adapted trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 358:1405-1412.
66. Ashkenazi S., Vertruyen A., Aristegui J., Esposito S., McKeith D.D., Klemola T., et al. Superior relative efficacy of live attenuated influenza vaccine compared with inactivated influenza vaccine in young children with recurrent respiratory tract infections. Pediatr Infect Dis J 2006, 25(10):870-879.
67. Tam J.S., Capeding M.R., Lum L.C., Chotpitayasunondh T., Jiang Z., Huang L.M., et al. Efficacy and safety of a live attenuated, cold-adapted influenza vaccine, trivalent against culture-confirmed influenza in young children in Asia. Pediatr Infect Dis J 2007, 26(7):619-628.
68. Rhorer J., Ambrose C.S., Dickinson S., et al. Efficacy of live attenuated influenza vaccine in children: a meta-analysis of nine randomized clinical trials. Vaccine 2009, 27(7):1101-1110.
69. Ambrose C.S., Levin M.J., Belshe R.B. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respir Viruses 2011, 5(2):67-75.
70. Monto A.S., Ohmit S.E., Petrie J.G., Johnson E., Truscon R., Teich E., et al. Comparative efficacy of inactivated and live attenuated influenza vaccines. N Engl J Med 2009, 361:1260-1267.
71. WHO. Global Vaccine Action Plan. http://www.who.int/immunization/global_vaccine_action_plan/SAGE_GVAP_Assessment_Report_2015_EN.pdf?ua=1.
72. Neuzil K.M., Bright R.A. Influenza vaccine manufacture: keeping up with change. J Infect Dis 2009, 200(6):835-837.
73. Rodriguez D. The revolving fund and the access to seasonal influenza vaccine in the Americas; 2013. http://www.who.int/influenza_vaccines_plan/resources/session_6_rodriguez.pdf.
74. GAVI Board Meeting November 21-22, 2013. http://www.gavi.org/about/governance/gavi-board/minutes/2013/21-nov/.
75. Omer S.B., Richards J.L., Madhi S.A., Tapia M.D., Steinhoff M.C., Aqil A.R., Wairagkar N. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: methods and expectations. Vaccine 2015, 33(32):3801-3812. BMGF Supported Maternal Influenza Immunization Trials Investigators Group.
76. Lambach P., Hombach J., Ortiz J.R. A global perspective of maternal influenza immunization. Vaccine 2015, 33(47):6376-6379.
77. Sobanjo-Ter Meulen A., Abramson J., Mason E., Rees H., Schwalbe N., Bergquist S., Klugman K.P. Path to impact: a report from the Bill and Melinda Gates Foundation convening on maternal immunization in resource-limited settings; Berlin-January 29-30, 2015. Vaccine 2015, 33(47):6388-6395.
78. Gessner B.D., Brooks W.A., Neuzil K.M., Vernet G., Bright R.A., Tam J.S., Bresee J., Monto A.S. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). Vaccine 2013, 31(32):3222-3228.